Table 1.
Clinical trials based on checkpoint blockade using mAbs against TIGIT.
| Clinical Trial Identifier | Condition or Disease | α-TIGIT mAb | Intervention | Phase | Recruitment Status April 2019 | Estimated Study Completion Date |
|---|---|---|---|---|---|---|
| NCT03119428 | Advanced Cancer, Metastatic Cancer | Etiligimab (OMP-313M32) | OMP-313M32; OMP-313M32 + Nivolumab | 1 | Active, not recruiting | October, 2019 |
| NCT03563716 | Non-small Cell Lung Cancer | Tiragolumab (MTIG7192A) | MTIG7192A Atezolizumab; Placebo + Atezolizumab | 2 | Active, not recruiting | February, 2021 |
| NCT03628677 | Advanced solid tumors | AB154 | AB154; AB154 + anti-PD1 (AB122) | 1 | Recruiting | February, 2020 |
| NCT02964013 | Advanced solid tumors | MK-7684 | MK-7684; MK-7684+ Pembrolizumab | 1 | Recruiting | June, 2022 |
| NCT02913313 | Advanced solid tumors | BMS-986207 | BMS-986207; BMS-986207 + anti-PD1 | 1/2 | Recruiting | December, 2022 |
| NCT03260322 | Advanced solid tumors | ASP8374 | ASP8374; ASP8374+ Pembrolizumab | 1 | Recruiting | July, 2021 |
| NCT03945253 | Advanced solid tumors | ASP8374 | ASP8374 | 1 | Not yet recruiting | December, 2022 |